RecruitingNot ApplicableNCT06891183

Percutaneous Thermal Ablation in Lung Tumors

Percutaneous Thermal Ablation in Treatment of Lung Cancer


Sponsor

Assiut University

Enrollment

50 participants

Start Date

May 1, 2023

Study Type

INTERVENTIONAL

Conditions

Summary

Lung cancer has a high incidence globally, with Egypt having it as the third most common and most lethal cancer, affecting 16.9% of males and 3.8% of females. While surgery is the preferred treatment for stage 1 non-small cell lung cancer due to positive outcomes, it carries significant risks due to patient comorbidities. Non-invasive treatments like radio frequency ablation (RFA) and microwave ablation (MWA) are alternatives for those unable to undergo surgery. These techniques use energy to destroy tumor tissue with minimal invasiveness and can be guided by computed tomography to ensure accurate ablation.


Eligibility

Inclusion Criteria3

  • lung cancer smaller than 5 cm
  • metastasis to the lung
  • patients with lung cancer and multiple comorbidities who are unfit for surgery

Exclusion Criteria3

  • lung cancer larger than 5 cm
  • lung cancer stage II or more
  • patients who cannot tolerate CT guided needle placement for thermal ablation of lung tumors

Interventions

RADIATIONPercutaneous thermal ablation of lung tumors

Percutaneous radiofrequency ablation


Locations(1)

Faculty of medicine

Asyut, Egypt

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06891183


Related Trials